

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
06 January 2022 (06.01.2022)



(10) International Publication Number
WO 2022/006537 A1

(51) International Patent Classification:
A61K 31/4709 (2006.01) *A61P 25/00* (2006.01)
A61K 31/4725 (2006.01)

(21) International Application Number:
PCT/US2021/040339

(22) International Filing Date:
02 July 2021 (02.07.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/047,359 02 July 2020 (02.07.2020) US

(71) Applicant: SEA PHARMACEUTICALS LLC [US/US];
14 Gray Street, Cambridge, Massachusetts 02138 (US).

(72) Inventors: PEARSON, James Philip; 14 Gray Street,
Cambridge, Massachusetts 02138 (US). MARTINEZ, Edu-
ardo J.; 632 Dayton Rd., Bryn Mawr, Pennsylvania 19010
(US).

(74) Agent: BRULE, Christina E.; HESLIN ROTHENBERG
FARLEY & MESITIP.C., 5 Columbia Circle, Albany, New
York 12203 (US).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: PHARMACEUTICAL COMPOSITIONS OF 6-(2-(2H-TETRAZOL-5-YL)ETHYL)-6-FLUORODECAHYDROIS
OQUINOLINE-3-CARBOXYLIC ACID AND ESTER DERIVATIVES THEREOF





FIG. 15A



(57) Abstract: 6-(2-(2H-tetrazol-5-yl)ethyl)-6-fluorodecahydroisoquinoline-3-carboxylic acid and 6-(2-(2H-tetrazol-5-yl)ethyl)-6-flu-
orodecahydroisoquinoline-3-carboxylic acid hydrocarbyl ester derivatives of formula are disclosed, as are pharmaceutical compositions
and methods for the treatment of pain, epilepsy, convulsions, and seizures employing those compositions.

[Continued on next page]

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to the identity of the inventor (Rule 4.17(i))*

Published:

— *with international search report (Art. 21(3))*